Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VK2735-102 part 1 subcutaneous maintenance

63 evidence topics · 9 sources

Objective
Location and study date
Study dates and United States sites in the ClinicalTrials.gov record
FieldRegistry value
Study start (actual)“2025-11-18”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-07”
First posted“2026-09-24”
Site 1“Viking Clinical Site #001”
Site 1 city“Lake Forest”
Site 2“Viking Clinical Site #002”
Site 2 city“Miami”
Study design
Eligibility criteria
Age range in the ClinicalTrials.gov record
FieldRegistry value
Minimum age“18 Years”
Maximum age“60 Years”
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the induction efficacy population
GroupParticipants analyzed at week 21
Placebo“(n=15)”
VK2735 15 mg weekly“(n=14)”
VK2735 17.5 mg weekly“(n=118)”
VK2735 20 mg weekly“(n=15)”
VK2735 22.5 mg weekly“(n=14)”
Participants analyzed in the maintenance period
GroupEfficacy populationSafety population
Placebo after 17.5 mg weekly“(n=27)”“(n=27)”
VK2735 combined every other week“(n=37)”“(n=37)”
VK2735 combined monthly“QM (n=65)”“QM (n=66)”
Description of analysis sets
Results
Participant disposition
Discontinuations during the 21-week induction period
OutcomePlacebo (n=15)VK2735 combined (n=166)15 mg weekly (n=15)17.5 mg weekly (n=121)20 mg weekly (n=15)22.5 mg weekly (n=15)
Discontinued treatment early“0 (0%)”“22 (13%)”“2 (13%)”“15 (12%)”“1 (7%)”“4 (27%)”
Discontinued treatment due to adverse event“0 (0%)”“1 (1%)”“0 (0%)”“1 (1%)”“0 (0%)”“0 (0%)”
Discontinuations during the every-other-week maintenance period
OutcomePlacebo (n=27)VK2735 combined (n=37)5.0 mg (n=12)7.5 mg (n=13)10.0 mg (n=12)
Discontinued treatment early“0 (0 %)”“1 (3 %)”“0 (0 %)”“0 (0 %)”“1 (8 %)”
Discontinued treatment due to adverse event“0 (0 %)”“1 (3 %)”“0 (0 %)”“0 (0 %)”“1 (8 %)”
Discontinuations during the monthly maintenance period
OutcomePlacebo (n=27)VK2735 combined (n=66)10 mg (n=16)15 mg (n=14)17.5 mg (n=11)20 mg (n=14)22.5 mg (n=11)
Discontinued treatment early“0 (0 %)”“3 (5 %)”“0 (0 %)”“1 (7 %)”“1 (9 %)”“1 (7 %)”“0 (0 %)”
Discontinued treatment due to adverse event“0 (0 %)”“1 (2 %)”“0 (0 %)”“0 (0 %)”“0 (0 %)”“1 (7 %)”“0 (0 %)”
Baseline characteristics
Mean baseline body weight by induction dose
GroupMean baseline body weight
Placebo (n=15)“100.0 kg”
VK2735 15 mg weekly (n=14)“108.4 kg”
VK2735 17.5 mg weekly (n=118)“95.9 kg”
VK2735 20 mg weekly (n=15)“101.9 kg”
VK2735 22.5 mg weekly (n=14)“103.0 kg”
Efficacy results
Change in body weight after 21 weeks of weekly dosing
MeasurePlacebo (n=15)15 mg weekly (n=14)17.5 mg weekly (n=118)20 mg weekly (n=15)22.5 mg weekly (n=14)
Mean change from baseline body weight“-0.1 kg”“-17.0 kg”“-17.0 kg”“-18.6 kg”“-17.2 kg”
Mean percent change from baseline“-0.1 %”“-16.3 %”“-17.8 %”“-18.7 %”“-17.1 %”
Placebo-adjusted mean percent change from baseline“-”“-16.2 %”“-17.7 %”“-18.6 %”“-17.0 %”
p-value vs. placebo“-”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing
MeasurePlacebo (n=27)Combined every other week (n=37)17.5 mg weekly to 5.0 mg every other week (n=12)15.0 mg weekly to 7.5 mg every other week (n=13)17.5 mg weekly to 10.0 mg every other week (n=12)
Mean percentage of week 21 weight loss maintained at week 33“61 %”“90 %”“83 %”“90 %”“97 %”
p-value vs. placebo“-”“p<0.0001”“0.004”“<0.0001”“<0.0001”
Percentage of week 21 weight loss maintained at week 33 with monthly dosing
MeasurePlacebo (n=27)Combined monthly (n=65)17.5 mg weekly to 10 mg monthly (n=16)17.5 mg weekly to 15 mg monthly (n=14)17.5 mg weekly to 17.5 mg monthly (n=11)20 mg weekly to 20 mg monthly (n=14)22.5 mg weekly to 22.5 mg monthly (n=10)
Mean percentage of week 21 weight loss maintained at week 33“61 %”“85 %”“82 %”“84 %”“90 %”“86 %”“85 %”
p-value vs. placebo“-”“<0.0001”“0.0016”“0.0012”“0.0002”“0.0005”“0.0024”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events and gastrointestinal adverse events through week 21
Adverse events after transition to every-other-week dosing
Adverse events after transition to monthly dosing
Study limitations
Summary: study limitations

Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.